NCT03158948 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 3, 2017

Primary Completion Date

June 13, 2018

Study Completion Date

June 13, 2018

Conditions

Shock, Septic

Interventions

DRUG

Nangibotide 0.3 mg/kg

Formulated LR12 peptide

DRUG

Placebo

placebo

DRUG

Nangibotide 1 mg/kg

Formulated LR12 peptide

DRUG

Nangibotide 3 mg/kg

Formulated LR12 peptide

Trial Locations (4)

Cliniques Universitaires Saint-Luc (there may be other sites in this country), Brussels

Inserm Clinical Investigational Center, CHU Dupuytren (there may be other sites in this country), Limoges

Radboudumc (there may be other sites in this country), Nijmegen

Hospital Clínico San Carlos, Medicina Intensiva (there may be other sites in this country), Madrid